A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
Completed · Phase 1
Conditions studied: Schizophrenia
In brief
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters. This study is accepting male and female participants age 18 years to 65 years. This study will be conducted in approximately 6 study sites in the United States. Participation could last up to 13 weeks.
Key facts
- Study ID
- NCT05542264
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- People needed
- 19
- Starts
- 2022-11-15
- Expected to finish
- 2024-02-12
- Last updated by the study team
- 2024-06-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Woodland International Research Group — Little Rock, Arkansas, United States
- Shari DeSilva — Rogers, Arkansas, United States
- Midwest Clinical Research Center — Dayton, Ohio, United States
- Endeavor Clinical Trials — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.